Metoprolol’s most frequently reported side effects are fatigue, dizziness, and a slow heart rate, but the drug can affect everything from sleep quality to sexual function to exercise capacity. Because metoprolol is one of the most widely prescribed beta-blockers in the world, used for high blood pressure, heart failure, and post-heart-attack care, millions of people take it daily and experience its effects differently depending on dose, formulation, genetics, and what other medications they use. The side-effect profile is broader than many patients expect, and some of the most troublesome effects are the ones no one warned them about.
Fatigue and Reduced Exercise Tolerance
Fatigue is the side effect that bothers people the most in practice, partly because it is so persistent and hard to pin down. A large analysis pooling data from over 35,000 participants across 15 trials found that beta-blockers were associated with roughly 18 additional reports of fatigue per 1,000 patients per year, which works out to about one extra person reporting fatigue for every 57 treated.1PubMed. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction That sounds modest on paper, but it likely underestimates what patients actually feel, since clinical trials tend to capture only what gets formally reported.
The fatigue is not just subjective tiredness. Beta-blockers limit how fast your heart can beat during exertion, which directly caps your exercise capacity. In healthy volunteers, metoprolol reduced endurance by about 15% and made exercise feel harder at the same workload.2PubMed Central. The effect of beta-adrenoceptor blockade on factors affecting exercise tolerance in normal man Another trial showed that beta-blockers significantly prolonged the time it took healthy subjects to complete exercise and increased their perception of fatigue.3PubMed Central. Influence of debrisoquine oxidation phenotype on exercise tolerance and subjective fatigue after metoprolol and atenolol in healthy subjects If you have started metoprolol and feel like your usual run or bike ride suddenly became much harder, you are not imagining it. The drug is literally preventing your heart from reaching the rates it used to hit.
One practical detail that matters: the slow-release (succinate) formulation causes less of a spike in blood levels than the immediate-release (tartrate) version. In one small trial, a single 200 mg dose of standard metoprolol significantly reduced maximal exercise power, while the same dose in slow-release form did not.4PubMed. Maximal exercise power after a single dose of metoprolol and of slow-release metoprolol The formulation you take can make a real difference in how the fatigue hits.
Slow Heart Rate and Low Blood Pressure
Metoprolol works by blocking the receptors that speed up your heart, so a slower heart rate is the whole point. The problem is when it slows too much. Bradycardia, a heart rate that dips below what your body needs, is a dose-dependent risk. Higher daily doses consistently produce more cases of problematically slow heart rates.5PubMed Central. Risk of Emergent Bradycardia Associated with Initiation of Immediate- or Slow-Release Metoprolol
The immediate-release formulation carries a higher risk here as well. At the same total daily dose, the immediate-release version produces peak blood concentrations roughly two to three times higher than the extended-release version, which translates into a sharper heart-rate dip at peak drug levels. One comparison found that the immediate-release form at 50 mg twice daily reduced heart rate by about 19% from baseline, compared with about 13% for the extended-release 100 mg taken once daily.6PubMed Central. Risk of Emergent Bradycardia Associated with Initiation of Immediate- or Slow-Release Metoprolol That six-percentage-point gap can be the difference between feeling fine and feeling dizzy when you stand up.
Dizziness and lightheadedness from low blood pressure are closely related. Metoprolol lowers blood pressure on top of slowing the heart, and the two effects together can leave you feeling faint, especially when standing quickly. A comparative study found that fatigue and dizziness were the most common adverse reactions overall, and that the extended-release succinate formulation had a better safety profile than immediate-release tartrate.7Vascular & Endovascular Review. Comparative Study of Metoprolol Succinate and Metoprolol Tartrate: Therapeutic Efficacy and Safety through Oral and Nasogastric Tube Administration
Sleep Problems, Vivid Dreams, and Mood Changes
Metoprolol is moderately lipophilic, meaning it dissolves readily in fat and crosses into the brain more easily than water-soluble beta-blockers like atenolol. That brain penetration is why it can cause neuropsychiatric side effects that feel oddly disconnected from a heart medication. The most commonly reported are vivid or bizarre dreams, sleep disturbances, and occasionally visual hallucinations or delirium.8PubMed Central. Metoprolol-Associated Central Nervous System Complications
A comprehensive review comparing four beta-blockers found that the overall rate of these central nervous system effects is generally low at standard doses. Among the four drugs examined, the water-soluble atenolol had the fewest such reports, while the highly fat-soluble propranolol and pindolol had the most. Metoprolol fell in the middle.9Pharmacology & Therapeutics. Beta-blockers and central nervous system side effects If you are having disturbing dreams or trouble sleeping on metoprolol, switching to a more hydrophilic beta-blocker is a conversation worth having with your prescriber.
The question of depression is more contentious. The large pooled analysis of over 35,000 subjects found no statistically significant increase in depressive symptoms with beta-blocker therapy, which challenges the long-standing clinical belief that beta-blockers cause depression.10PubMed. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction However, a study focused specifically on heart failure patients who already had neuropsychiatric conditions found that metoprolol did worsen depression scores, especially in patients who had both depression and high burnout at baseline. In those patients, depressive symptoms increased significantly within the first month and stayed elevated throughout a year of follow-up.11PubMed Central. Impact of metoprolol treatment on mental status of chronic heart failure patients with neuropsychiatric disorders The takeaway is that metoprolol probably does not cause depression out of nowhere in most people, but it may make existing depression worse in vulnerable individuals.
Sexual Dysfunction
Sexual side effects are underreported in clinical trials but common in clinical practice, and they are one of the top reasons people stop taking beta-blockers. Metoprolol has been specifically shown to worsen erectile function. In a trial of hypertensive men, metoprolol significantly decreased erectile function scores within the first eight weeks of treatment, while nebivolol, a newer beta-blocker, did not.12PubMed. Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men Another study in men after coronary bypass surgery found that about 86% of those on metoprolol experienced some degree of erectile dysfunction, compared with 84% on nebivolol, and while the absolute numbers were high in both groups, the difference was statistically significant.13PubMed Central. The Comparison of the Effects of Nebivolol and Metoprolol on Erectile Dysfunction in the Cases with Coronary Artery Bypass Surgery
The large pooled analysis acknowledged that beta-blockers carry only a “small” increased risk of sexual dysfunction and argued that the conventional wisdom overstates the problem.14PubMed. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction But clinical experience and head-to-head trials paint a slightly different picture, especially compared with newer agents like nebivolol that promote nitric oxide release. If sexual side effects are an issue for you, this is not something to suffer through in silence. Alternatives exist.
Weight Gain
Weight gain on older-generation beta-blockers like metoprolol is real, though the mechanism is not as simple as “the drug makes you eat more.” Part of it comes from the reduction in resting metabolic rate. Beta-blockers dampen the sympathetic nervous system, which is part of what drives calorie burning at rest. Part of it is the exercise limitation already discussed: if your workouts feel harder and you do less, you burn fewer calories over time.
A controlled dietary study found that overweight and obese patients on older beta-blockers (including metoprolol) lost significantly less weight over six months and two years compared with patients on no beta-blockers or on newer third-generation agents. At two years, the older beta-blocker group had lost about 9% of their total weight, while the non-beta-blocker group lost about 13%, and the third-generation beta-blocker group did even better at roughly 16%.15PubMed Central. Effect of Third-Generation Beta Blockers on Weight Loss in a Population of Overweight-Obese Subjects in a Controlled Dietary Regimen A separate matched analysis found that long-term antihypertensive therapy did not significantly alter resting energy expenditure when measured directly, but that self-reported weight gain at the start of therapy was more common in patients on beta-blockers than in those on other antihypertensives.16Clinical Nutrition ESPEN. Impact of use of antihypertensive drugs on resting energy expenditure and body composition: A matched-pair analysis of users and non-users So while metoprolol may not fundamentally rewire your metabolism, it can quietly tilt the scales in the wrong direction, especially over months and years.
Breathing Difficulties in People with Asthma or COPD
Metoprolol is marketed as a “cardioselective” beta-blocker, meaning it preferentially acts on the heart’s beta-1 receptors rather than the beta-2 receptors in the lungs. But that selectivity is relative, not absolute, and it weakens at higher doses. In a study of asthmatic patients given escalating doses of metoprolol, the average maximum tolerated dose was only about 27 mg before airway function deteriorated enough to stop the test. One patient had to be dropped entirely because of severe bronchoconstriction after a single low dose.17PubMed. Respiratory and cardiac effects of metoprolol and bevantolol in patients with asthma Those doses are well below the typical therapeutic range, which usually starts at 50 mg or higher.
In COPD patients, metoprolol lowered the threshold for airway hyperresponsiveness to a similar degree as the non-selective propranolol, though it did not worsen baseline lung function as much.18CHEST. Differential Effects of β-Blockers on Pulmonary Function in COPD The practical upshot: if you have asthma, metoprolol is risky and generally avoided. If you have stable COPD, it is sometimes used carefully, but your lung function should be monitored.
Cold Hands and Skin Reactions
Cold extremities are a classic beta-blocker complaint. By blocking the receptors that help blood vessels dilate, metoprolol can reduce blood flow to the fingers and toes. This is especially problematic for people who already have Raynaud’s syndrome, where blood flow to the digits shuts down in response to cold or stress. Beta-blockers including metoprolol are listed among the drugs that can trigger or worsen Raynaud’s episodes.19PubMed Central. Immunologic adverse reactions of β-blockers and the skin
Other skin-related side effects are less common but well-documented. Beta-blockers have been associated with triggering or worsening psoriasis, causing hair thinning (alopecia), and producing excessive sweating. Contact dermatitis, lichen planus-like eruptions, and vitiligo are also reported, though these are rare.20PubMed Central. Immunologic adverse reactions of β-blockers and the skin If you develop a new skin condition after starting metoprolol, it is worth considering the drug as a possible cause.
Masking Low Blood Sugar in Diabetes
A long-standing concern with beta-blockers is that they could mask the warning signs of hypoglycemia in people with diabetes, particularly the racing heartbeat and shakiness that normally alert someone that their blood sugar is dropping. Metoprolol does block the heart rate response to low blood sugar. However, research suggests it does not make the hypoglycemia itself worse and does not blunt all warning symptoms. In insulin-dependent diabetics, metoprolol actually increased sweating during hypoglycemia, which could serve as an alternative warning sign.21PubMed. Effects of metoprolol on the counter-regulation and recognition of prolonged hypoglycemia in insulin-dependent diabetics A separate study in healthy subjects found that while metoprolol blocked the tachycardia of hypoglycemia, it did not mask overall symptoms, and sweating was enhanced and prolonged.22Metabolism. Beta blockade and diabetes mellitus: Effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in normal subjects
So the fear that metoprolol will leave you completely unaware of a dangerous sugar drop is overstated, but it does remove one of the most obvious warning signals. If you have diabetes and take metoprolol, relying on a continuous glucose monitor rather than symptoms alone is a reasonable precaution.
Why Genetics Change the Equation
Metoprolol is broken down in the liver primarily by an enzyme called CYP2D6, and genes for this enzyme vary enormously from person to person. About 6 to 10% of people of European descent are “poor metabolizers,” meaning their CYP2D6 barely works. In these individuals, the same dose of metoprolol produces dramatically higher blood levels. One study found that poor metabolizers had drug concentrations over six times higher than normal metabolizers after adjusting for dose.23PubMed. Impact of genotype-predicted CYP2D6 metabolism on clinical effects and tolerability of metoprolol in patients after myocardial infarction – a prospective observational study
Higher blood levels mean more side effects. A retrospective study found that poor metabolizers had significantly higher odds of developing bradycardia, with the risk increasing further with age.24PubMed Central. Metoprolol and CYP2D6: A Retrospective Cohort Study Evaluating Genotype-Based Outcomes If you seem unusually sensitive to metoprolol, experiencing pronounced side effects even at low doses, a CYP2D6 genetic test can explain why and help your prescriber adjust accordingly.
Dangerous Interactions with Common Antidepressants
Because CYP2D6 is so central to metoprolol clearance, any drug that inhibits that enzyme effectively turns a normal metabolizer into a poor one. Three widely prescribed antidepressants do exactly this: paroxetine (Paxil), fluoxetine (Prozac), and bupropion (Wellbutrin). Paroxetine has been shown to increase the effective dose of metoprolol in the body by roughly four- to six-fold.25PubMed. Interactions between metoprolol and antidepressants That is the pharmacological equivalent of accidentally taking several times your prescribed dose.
The consequences can be serious. Severe bradycardia and atrioventricular block have been reported in patients combining metoprolol with these antidepressants.26PubMed. Interactions between metoprolol and antidepressants In one published case, a 63-year-old woman on paroxetine developed complete heart block after starting metoprolol, which resolved after paroxetine was discontinued. Neither drug alone had caused the problem.27PubMed. Complete atrioventricular block associated with concomitant use of metoprolol and paroxetine A systematic review of the interaction confirmed that the majority of published evidence suggests the combination can cause clinically meaningful harm.28PubMed Central. The impact of CYP2D6 mediated drug–drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine
This interaction is underprescribed in public awareness. Many people take a beta-blocker for their heart and an antidepressant for their mood without anyone flagging the overlap. If you are on metoprolol and one of these three drugs, your doctor or pharmacist should be aware. Alternative antidepressants that do not strongly inhibit CYP2D6 (sertraline and citalopram, for instance) are typically safer choices.
What Happens When You Stop
You should never stop metoprolol abruptly. Beta-blockers cause the body to upregulate its sensitivity to adrenaline over time, and when the blocking drug is suddenly removed, the heart responds to adrenaline more intensely than it did before treatment started. One study measured a 52% rebound increase in cardiac sensitivity to stimulation and a 15% rebound rise in resting heart rate within two to eight days of stopping metoprolol.29PubMed. Metoprolol withdrawal phenomena: mechanism and prevention
Even with gradual tapering, rebound effects can occur. A study in patients with ischemic heart disease found that resting heart rate and heart-rate responses to position changes remained elevated for three weeks after gradual withdrawal, only returning to true baseline months later.30American Heart Journal. Rebound phenomena following gradual withdrawal of chronic metoprolol treatment in patients with ischemic heart disease For people with angina or coronary artery disease, these rebound effects can unmask chest pain or provoke dangerous heart rhythms. The standard advice of tapering over one to two weeks is not overly cautious; it is based on how the physiology works.
Liver Disease and Older Adults
Metoprolol is almost entirely cleared by the liver, which means liver damage can substantially raise drug levels. In patients with cirrhosis, the drug’s elimination half-life was about 7.2 hours compared with 4.2 hours in healthy controls, meaning the drug lingers nearly twice as long.31PubMed. Pharmacokinetics of metoprolol in patients with hepatic cirrhosis This prolonged exposure increases the likelihood of every side effect discussed above. Dose reductions are usually necessary.
Older adults face a similar accumulation issue for a different reason. CYP2D6 activity can decline with age, and kidney and liver function generally decrease. The genetic study on CYP2D6 phenotype found that age was a significant independent driver of bradycardia risk on metoprolol, layering on top of whatever genetic predisposition a patient already had.32PubMed Central. Metoprolol and CYP2D6: A Retrospective Cohort Study Evaluating Genotype-Based Outcomes Starting low and increasing gradually is particularly important in this group.
Tartrate Versus Succinate and Why It Matters for Side Effects
The two commercially available forms of metoprolol are tartrate (immediate-release, typically dosed twice daily) and succinate (extended-release, once daily). From a side-effect perspective, the succinate version almost always comes out ahead. Its smoother blood-level curve avoids the high peaks that trigger the worst bradycardia, exercise intolerance, and fatigue. The research on formulation differences consistently shows that the extended-release form produces less heart-rate suppression at peak and a lower incidence of emergent bradycardia at equivalent daily doses.33PubMed Central. Risk of Emergent Bradycardia Associated with Initiation of Immediate- or Slow-Release Metoprolol
If you are currently on metoprolol tartrate and struggling with side effects, asking about a switch to succinate is one of the simplest changes that can make a meaningful difference. The total daily dose stays roughly the same, but the ride gets much smoother. In settings where the drug is given through a nasogastric tube (common in hospitalized patients), the comparison still favors the succinate formulation for both efficacy and tolerability.34Vascular & Endovascular Review. Comparative Study of Metoprolol Succinate and Metoprolol Tartrate: Therapeutic Efficacy and Safety through Oral and Nasogastric Tube Administration